Mechanistically, FTY720 reduces GPX4 and SLC7A11 levels by activating protein phosphatase 2A (PP2A), which dephosphorylates the AMP-activated protein kinase α subunit (AMPKα) at the Thr172 site, subsequently reducing phosphorylated eukaryotic elongation factor 2 (eEF2), finally leading to MM ferrotposis. The gene discussed is GPX4; the disease is Miyoshi myopathy.